Biohaven Ltd.

NYSE: BHVN · Healthcare · Biotechnology

PublicHQ New Haven, CT · New HavenCIK 0001935979Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 25DQ —GM —SS 58

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ return on equity, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$738.8M

Employees

274

as of 2026-08-09

Market cap

$2.2B

as of 2026-08-09

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$738.8M-$738.8M2025

Operating income-$745.4M-$745.4M2025

Total assets$451.4M$451.4M2025

Liabilities$399.4M$399.4M2025

Equity$52.1M$52.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Biohaven Ltd.’s financial profile?

Biohaven Ltd. earned -$738.8M in FY2025 net income.

Peers · Healthcare

Mineralys Therapeutics, Inc.——Vera Therapeutics, Inc.——Sionna Therapeutics, Inc.——Kailera Therapeutics, Inc.——Rapport Therapeutics, Inc. Common Stock——Braveheart Bio, Inc.——

Neighbors

New Haven →

Veradermics, Incorporated——Trevi Therapeutics, Inc.——Arvinas, Inc.$262.6M61C Rallybio Corporation$858.0k47D Precipio, Inc.$24.2M69B BioXcel Therapeutics, Inc.$642.0k27D

Key facts

CEOVladimir Coric

SectorHealthcare

IndustryBiotechnology

HeadquartersNew Haven, CT

ExchangeNYSE: BHVN

Employees274

IPO date2022-09-23

Latest filings

8-K2026-08-26 10-Q2026-08-10 8-K2026-08-10 8-K2026-08-07 8-K2026-07-09 8-K2026-05-27 8-K2026-05-05 8-K2026-05-04

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.